Related Experiment Videos
Pharmacological intervention in prediabetes: considering the risks and benefits
S Del Prato1, C Bianchi, R Miccoli
1Department of Endocrinology and Metabolism, Section of Metabolic Diseases and Diabetes, University of Pisa, Pisa, Italy. delprato@immr.med.unipi.it
Diabetes, Obesity & Metabolism
|October 18, 2007
Summary
The growing diabetes epidemic requires social education and targeted interventions. Careful risk-benefit analysis is crucial for drug treatments to prevent type 2 diabetes and its complications.
Area of Science:
- Endocrinology and Metabolic Diseases
- Public Health
- Pharmacology
Background:
- The global diabetes epidemic presents significant individual and societal costs.
- Lifestyle factors are major drivers of increasing diabetes prevalence.
- Preventing progression from prediabetes to type 2 diabetes mellitus (T2DM) requires careful consideration of intervention costs, risks, and benefits.
Purpose of the Study:
- To evaluate the risk-benefit profile of pharmacological interventions for T2DM primary prevention.
- To highlight the challenges in assessing interventions for asymptomatic individuals at risk of T2DM.
- To emphasize the need for personalized treatment strategies in diabetes prevention.
Main Methods:
- Review of existing literature on T2DM prevention strategies.
- Analysis of risk-benefit assessments for pharmacological interventions.
- Consideration of pathogenetic mechanisms underlying impaired glucose regulation.
Main Results:
- Pharmacological interventions carry risks, including adverse effects in asymptomatic populations.
- A significant proportion of individuals may not progress to T2DM without treatment.
- Current risk-benefit assessments may not adequately account for diverse pathogenetic mechanisms.
Conclusions:
- Social and educational initiatives are essential for addressing the diabetes epidemic.
- Drug interventions for T2DM prevention require rigorous risk-benefit evaluation, considering potential adverse effects.
- Improved methods are needed to identify patients who will benefit most from safe and effective glucose-lowering treatments to prevent T2DM and cardiovascular outcomes.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...